Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...

reducing NFKBIA mRNA stability via m6A modification, thereby activating the NF-κB pathway. This study identifies a novel regulatory axis in osteoarthritis pathogenesis.

Among the 7MM, Japan accounts for the second highest total aplastic anemia drugs market. The Aplastic Anemia Treatment Market ...

In the following two articles, the pathophysiology, medical management, and nursing care of patients are discussed. An in-depth model care plan illustrates the complexity of the disease and its ...

Immunopathogenesis is the process of disease development involving an immune response or components thereof. Interrogation of electronic health records and the B and T cell repertoires of people ...